Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child–Pugh B liver function at study week 8: a retrospective analysis of the...

by Abou-Alfa, G.K, Cheng, A.-L, El-Khoueiry, A.B, Kelley, R.K, Meyer, T., Milwee, S., Rimassa, L., Sen, S.
Published 2022

Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child–Pugh B liver function at study week 8: a retrospective analysis of the...

by Abou-Alfa, G.K, Cheng, A.-L, El-Khoueiry, A.B, Kelley, R.K, Meyer, T., Milwee, S., Rimassa, L., Sen, S.
Published 2022

Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

by Breder, V., Cheng, A.-L, Ducreux, M., Finn, R.S, Galle, P.R, Ikeda, M., Kaseb, A.O, Kim, T.-Y, Kudo, M., Li, D., Li, L., Lim, H.Y, Ma, N., Merle, P., Nicholas, A., Qin, S., Verret, W., Wang, Y., Zhu, A.X
Published 2022

Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib

by Cattan, S., Chan, S.L, Cheng, A.-L, Daniele, B., Edeline, J., Fartoux, L., Finn, R.S, Gurary, E.B, KEYNOTE-224 Investigators, Knox, J., Kudo, M., Ogasawara, S., Palmer, D.H, Sarker, D., Siegel, A.B, Verset, G., Verslype, C., Vogel, A., Wang, A., Yau, T., Zagonel, V., Zhu, A.X
Published 2022